Simplify Logo

Full-Time

Associate Engineer

Msat

Posted on 7/15/2024

Umoja Biopharma

Umoja Biopharma

201-500 employees

Develops in vivo CAR T-cell therapies

Hardware
AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$31.5 - $38.25Hourly

Junior

Lafayette, CO, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • 2 years of experience in process development or biopharmaceutical manufacturing
  • Hands-on experience with cell passaging and buffer preparation
  • B.S in Biology, Bioengineering, Chemical Engineering, Biotechnology or related discipline
  • Excellent communication skills
  • Previous lab experience
  • Experience with viral vectors (e.g., AAV, LVV) is a plus
  • Experience with process equipment (Bioreactors, AKTA, peristaltic pumps, pH probes, conductivity meters) is a plus
  • Self-motivation, organization, effective communication, and presentation skills
  • Ability to work in a fast-paced environment
Responsibilities
  • Assist with experimental design, execution, and analysis for gene therapy product development
  • Collaborate with team members on tech transfer processes
  • Perform routine laboratory work to support MSAT lab operations
  • Maintain clear records of experimental work using an electronic notebook system
  • Communicate data in cross-functional meetings

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to other treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.

Company Stage

Series B

Total Funding

$271M

Headquarters

Seattle, Washington

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

17%

2 year growth

46%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with AbbVie, valued at up to $1.44 billion, provides substantial financial backing and validation of Umoja's technology.
  • Umoja's appointment of experienced executives like Britton Russell as CFO indicates strong leadership capable of guiding the company through growth phases.
  • Being recognized as one of the thriving biotechs in Seattle underscores Umoja's prominence and potential in the biotech industry.

What critics are saying

  • The success of Umoja's in vivo CAR T-cell therapies is still contingent on clinical trial outcomes, which carry inherent uncertainties.
  • The competitive landscape in immunotherapy is intense, with numerous companies vying for market share, which could impact Umoja's growth.

What makes Umoja Biopharma unique

  • Umoja Biopharma's in vivo approach to reprogramming T cells is a significant departure from traditional ex vivo methods, offering a potentially more efficient and scalable solution.
  • Their proprietary CAR T-cell gene therapy platform is designed to be off-the-shelf, allowing for faster production and distribution compared to customized therapies.
  • Strategic partnerships with major players like AbbVie highlight Umoja's innovative edge and potential for significant market impact.
INACTIVE